John R Wunderlich Selected Research

John R Wunderlich Research Topics

Disease

43	Neoplasms (Cancer) 01/2019 - 05/2002
38	Melanoma (Melanoma, Malignant) 01/2017 - 05/2002
8	Neoplasm Metastasis (Metastasis) 11/2018 - 05/2002
3	Lymphopenia (Lymphocytopenia) 01/2017 - 05/2002
3	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 12/2015 - 09/2013
3	Testicular Neoplasms (Testicular Cancer) 05/2014 - 01/2006
2	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2019 - 05/2015
2	Ovarian Neoplasms (Ovarian Cancer) 11/2018 - 10/2006
2	Disease Progression 01/2017 - 12/2010
2	Uveal melanoma 01/2017 - 01/2016
2	Neutropenia 01/2017 - 04/2005
2	Thrombocytopenia (Thrombopenia) 01/2017 - 04/2005
2	Sarcoma (Soft Tissue Sarcoma) 03/2015 - 03/2011
2	Fowlpox 10/2009 - 08/2003
1	Carcinoma (Carcinomatosis) 01/2019
1	Infections 01/2017
1	Cholangiocarcinoma 05/2014
1	Adenocarcinoma 01/2014
1	Stomach Neoplasms (Stomach Cancer) 01/2014
1	Carcinogenesis 10/2009
1	Uveitis 07/2009
1	Hearing Loss (Hearing Impairment) 07/2009
1	Exanthema (Rash) 10/2006
1	Pneumocystis Pneumonia (Pneumocystis carinii Pneumonia) 04/2005
1	Kidney Neoplasms (Kidney Cancer) 05/2002

Drug/Important Bio-Agent (IBA)

15	Interleukin-2 (IL2)IBA 02/2015 - 05/2002
14	AntigensIBA 03/2015 - 08/2003
8	Neoplasm Antigens (Tumor Antigens)IBA 04/2016 - 05/2002
7	T-Cell Antigen Receptors (T-Cell Receptor)IBA 11/2018 - 10/2006
6	EpitopesIBA 11/2018 - 05/2002
5	Differentiation AntigensIBA 01/2016 - 05/2002
4	Biomarkers (Surrogate Marker)IBA 01/2019 - 12/2008
4	HLA-A*02:01 antigenIBA 03/2015 - 05/2002
4	VaccinesIBA 10/2009 - 08/2003
4	Peptides (Polypeptides)IBA 11/2006 - 05/2002
3	InterleukinsIBA 12/2010 - 08/2003
3	CytokinesIBA 12/2008 - 05/2002
2	HLA Antigens (Human Leukocyte Antigens)IBA 11/2018 - 12/2015
2	Immunoglobulins (Immunoglobulin)IBA 08/2017 - 05/2014
2	SuspensionsIBA 10/2012 - 12/2008
2	gp100 Melanoma AntigenIBA 10/2009 - 08/2003
2	MART-1 AntigenIBA 08/2009 - 05/2002
2	fludarabineIBA 04/2005 - 05/2002
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 04/2005 - 05/2002
2	Melanoma-Specific AntigensIBA 09/2003 - 05/2002
1	Mutant Proteins (Protein, Mutant)IBA 01/2019
1	HLA-DRB3 Chains (HLA DRB3)IBA 11/2018
1	ElementsIBA 11/2018
1	Carrier Proteins (Binding Protein)IBA 08/2017
1	HLA-DRB1 Chains (HLA DRB1)IBA 08/2017
1	VemurafenibIBA 01/2017
1	Melanins (Melanin)IBA 01/2016
1	PlatinumIBA 05/2015
1	AutoantigensIBA 02/2015
1	Monophenol Monooxygenase (Tyrosinase)IBA 05/2014
1	Proteins (Proteins, Gene)FDA Link 05/2014
1	Member 9 Tumor Necrosis Factor Receptor SuperfamilyIBA 05/2014
1	MucinsIBA 05/2014
1	HLA-C Antigens (HLA-C)IBA 01/2014
1	HLA-B Antigens (HLA-B)IBA 01/2014
1	RNA (Ribonucleic Acid)IBA 09/2013
1	Interferon-gamma (Interferon, gamma)IBA 06/2013
1	Programmed Cell Death 1 ReceptorIBA 11/2010
1	InterferonsIBA 11/2010
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 10/2009
1	Phosphotransferases (Kinase)IBA 10/2009
1	Lapatinib (GW572016)FDA Link 10/2009
1	Small Interfering RNA (siRNA)IBA 10/2009
1	Tyrosine (L-Tyrosine)FDA Link 10/2009
1	SteroidsIBA 07/2009
1	AgarIBA 05/2009
1	Matrix Metalloproteinases (MMPs)IBA 05/2009
1	Cancer VaccinesIBA 11/2006
1	IgG Receptors (Fc gamma RI)IBA 10/2006
1	Folic Acid (Vitamin M)FDA LinkGeneric 10/2006
1	ChemokinesIBA 10/2006
1	6-sulfo sialyl Lewis XIBA 10/2006
1	Decitabine FDA Link 01/2006
1	Glycoproteins (Glycoprotein)IBA 09/2003
1	beta 2-Microglobulin (beta 2 Microglobulin)IBA 09/2003
1	Amino Acids FDA Link 08/2003
1	flt3 ligand protein (flt3 ligand)IBA 05/2002

Therapy/Procedure

29	Therapeutics 01/2019 - 05/2002
14	Immunotherapy 01/2019 - 05/2002
11	Cell- and Tissue-Based Therapy (Cell Therapy) 11/2018 - 10/2008
11	Drug Therapy (Chemotherapy) 01/2017 - 05/2002
2	Aftercare (After-Treatment) 01/2019 - 05/2015
1	Chemoradiotherapy 05/2015
1	Metastasectomy 12/2010
1	Biological Therapy 10/2006
1	Intravenous Administration 09/2003